Kanashiro, C.A., Schally, A.V., Groot, K., Armatis, P., Bernardino, A.L. and Varga, J.L. (2003) Inhibition of Mutant p53 Expression and Growth of DMS-153 Small Cell Lung Carcinoma by Antagonists of Growth Hormone-Releasing Hormone and Bombesin. Proceedings of the National Academy of Sciences of the United States of America, 100, 15836-15841.
https://doi.org/10.1073/pnas.2536558100

has been cited by the following article:

• TITLE: Growth Hormone Releasing Hormone Receptors Antagonists and Cancers: Do GHRH-R Antagonists Play a Role in the Management of Prostate Cancer?

  AUTHORS: Joseph Bertin Alexis Zoa Bindzi, Yingjie Yang, Xiaoqi Yan, Yi Zhong, Yuantong Tian

  KEYWORDS: GHRH, Receptors, Antagonists, Prostate, Cancer

  JOURNAL NAME: Open Journal of Urology, Vol.10 No.6, May 28, 2020

  ABSTRACT: Growth hormone-releasing hormone (GHRH) and its receptors have been implicated in the progression of various tumors such as those of the prostate. Treatment modalities for prostate cancer in a localized stage or when it is still castration-sensitive yield good results in most patients. However, such treatments are only palliative in the advanced stage. Therefore, new therapeutic targets like growth hormone-releasing hormone receptor (GHRH-R) and its splice variants should be found in order to get effective treatments for more aggressive stages in prostate cancer. This review talks about the GHRH-R and its splice variants, the signaling pathways induced by GHRH to produce cancer, the structure activity relationship of GHRH-R antagonists and the resume of some in vitro and in vivo studies on the role of GHRH-R antagonists in the treatment of prostate cancer.